行情

ICPT

ICPT

Intercept制药
NASDAQ

实时行情|Nasdaq Last Sale

48.75
+1.57
+3.33%
盘后: 48.68 -0.07 -0.14% 19:44 08/07 EDT
开盘
47.18
昨收
47.18
最高
49.25
最低
46.20
成交量
71.94万
成交额
--
52周最高
125.00
52周最低
42.19
市值
16.06亿
市盈率(TTM)
-4.5464
分时
5日
1月
3月
1年
5年

分析师评级

24位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ICPT价格均价为66.32,最高价位140.00,最低价为46.00。

EPS

ICPT 新闻

更多
Why Earnings Season Could Be Great for Intercept (ICPT)
Intercept (ICPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 1天前
Did Hedge Funds Make The Right Call On Intercept Pharmaceuticals Inc (ICPT)?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which
Insider Monkey · 4天前
Intercept to Announce Second Quarter 2020 Financial Results on August 10, 2020
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its secon
GlobeNewswire · 5天前
Intercept Pharmaceuticals (ICPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Intercept (ICPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/29 16:33
Theratechnologies NASH Data And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha · 07/26 08:41
Intercept Pharma higher on activist chatter
A rumor making the rounds says a large activist may be getting involved with Intercept Pharma (NASDAQ:ICPT) to push for sale. Intercept disappointed in lat
seekingalpha · 07/16 19:43
Intercept Pharma 8-K Shows Co. Received Paragraph IV Certification Notice From Apotex Indicated Apotex Submitted To FDA Abbreviated New Drug Application Seeking Approval To Manufacture, Sell Generic Version Of Co.'s Ocaliva
On July 13, 2020, Intercept Pharmaceuticals, Inc. (the “Company”) received a paragraph IV certification notice (the “PIV Notice”) from Apotex Inc. (“Apotex”) indicating that Apotex has
Benzinga · 07/15 21:07
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14)
Benzinga · 07/15 11:30

所属板块

生物技术和医学研究
-0.18%
制药与医学研究
+0.08%

热门股票

代码
价格
涨跌幅

ICPT 简况

Intercept Pharmaceuticals, Inc.是一家生物制药公司。该公司专注于开发及商业化用于治疗非病毒性慢性肝病的药品。该公司的候选产品有潜力治愈难治疗的罕见病及流行病。其候选产品奥贝胆酸(OCA)是胆汁酸类似物,是一种拥有类似于自然产生的人体胆汁酸结构的化学物质。该胆汁酸选择性活化法呢醇X受体。该公司正在开发用于治疗肝病的OCA,如:原发性胆汁性肝硬化(PBC)、非酒精性脂肪性肝炎(NASH)、原发性硬化性胆管炎(PCS)以及胆管闭锁。该公司还开发其他产品,包括:用于治疗纤维变性的INT-767以及用于治疗二型糖尿病的INT-777。
展开

微牛提供Intercept Pharmaceuticals Inc(NASDAQ-ICPT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ICPT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ICPT股票基本功能。